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Abstract
Background: In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP)
significantly improved overall response rate and progression-free status compared with VMP alone in transplant-
ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes
(PROs) from ALCYONE.
Methods: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-
item (EORTC QLQ-C30) and EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire were administered
at baseline, every 3 months (year 1) and every 6 months (until progression). Treatment effects were assessed using a
repeated-measures, mixed-effects model.
Results: Compliance with PRO assessments was comparable at baseline (> 90%) and throughout study (> 76%) for
both treatment groups. Improvements from baseline were observed in both groups for EORTC QLQ-C30 Global
Health Status (GHS), most functional scales, symptom scales and EQ-5D-5L visual analog scale (VAS). Between-group
differences were significant for GHS (p = 0.0240) and VAS (p = 0.0160) at month 3. Improvements in pain were
clinically meaningful in both groups at all assessment time points. Cognitive function declined in both groups, but
the magnitude of the decline was not clinically meaningful.
Conclusions: Patients with transplant-ineligible NDMM demonstrated early and continuous improvements in health-
related quality of life, including improvements in functioning and symptoms, following treatment with D-VMP or VMP.
Trial registration: ClinicalTrials.gov identifier NCT02195479, registered September 21, 2014
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Background
Treatment approaches for newly diagnosed multiple
myeloma (NDMM) are chosen based on the patient’s
fitness; those considered fit usually receive induction,
high-dose chemotherapy and autologous stem cell trans-
plant (ASCT) as standard of care [1]. In patients ineli-
gible for ASCT, treatment with bortezomib, melphalan
and prednisone (VMP) or lenalidomide plus low-dose
dexamethasone is recommended [1]. Older patients and
those who are transplant ineligible have significantly
shorter relative survival than younger, fitter, transplant-
eligible patients [2, 3]. In addition to age, factors such as
frailty, performance status and comorbidities are import-
ant determinants of ASCT eligibility and treatment
selection in the frontline setting [4–6].
MM can profoundly impact patients’ daily lives,
imposing both physical (i.e. fatigue, mobility, pain and
physical activity) and emotional (i.e. distress, anxiety, de-
pression and effects on relationships) burdens [7, 8].
Maintaining health-related quality of life (HRQoL)
during treatment is an important goal in MM, with a
particular focus on understanding the long-term impact
of disease and treatment on patients [9]. However,
reports on HRQoL in the ASCT-ineligible population (in
particular) are limited.
In May 2018, the US Food and Drug Administration
approved daratumumab, an anti-CD38 humanized
monoclonal antibody, for use in combination with VMP
(D-VMP) in patients with NDMM who are ineligible for
ASCT. This approval was based on the results of the
multicenter, open-label, phase III ALCYONE trial
(NCT02195479), which demonstrated significantly
higher response rates, higher rates of minimal residual
disease negativity, and lower risk of disease progression
or death in patients who received D-VMP compared
with those receiving VMP alone. Prespecified subgroup
analyses showed the superiority of D-VMP over VMP in
patients 75 years of age or older (29.9% of patients in the
study) and those with poor prognosis [10]. Rates of
grade 3/4 hematologic events, including neutropenia,
thrombocytopenia and anemia, were higher in the D-
VMP group than in the VMP group [10].
Here, we present analyses from the ALCYONE clinical
trial evaluating the treatment effect of D-VMP on
patient-reported outcomes (PROs).
Methods
Study design and patients
Details of the multicenter, randomized, open-label,
active-controlled, parallel group ALCYONE trial have
been previously published [10]. Cycle length for D-VMP
and VMP was 6 weeks (cycles 1–9) and 4 weeks (cycle
10+), respectively. Eligible patients were randomized 1:1
to D-VMP (VMP [see below] plus intravenous daratumumab
16mg/kg [once weekly in cycle 1, every 3weeks in cycles 2–
9 and every 4weeks thereafter until disease progression or
unacceptable toxicity]) or VMP (subcutaneous bortezomib
1.3mg/m2 [cycle 1: twice weekly; cycles 2–9: 4 doses/cycle],
melphalan 9mg/m2 [days 1–4] and prednisone 60mg/m2
[days 1–4]).
The study was conducted at 162 sites in 25 countries.
Each study site’s local independent ethics committee or
institutional review board approved the study protocol.
This study was conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki and the International Conference on Harmon-
isation Good Clinical Practice guidelines and adhered to
CONSORT guidelines. All patients provided written in-
formed consent.
PROs
PROs (a secondary objective of the ALCYONE trial)
were assessed by the European Organisation for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire Core 30-item (EORTC QLQ-C30) [11] and the
EuroQol 5-dimensional descriptive system (EQ-5D-5L)
[12]. The EORTC QLQ-C30 v3 is a validated, cancer-
specific instrument that contains 30 items resulting in
five functional scales (physical, role, emotional, cognitive
and social functioning), one Global Health Status (GHS)
scale, three symptom scales (fatigue, nausea and vomit-
ing, and pain) and six single items (dyspnea, insomnia,
appetite loss, constipation, diarrhea and financial diffi-
culties) [11]. Higher scores represent greater GHS, better
functioning and worse symptoms, respectively. The EQ-
5D-5L, a generic measure of health status, assesses five
domains including mobility, self-care, usual activities,
pain/discomfort and anxiety/depression plus a visual
analog scale (VAS) rating of “health today” [12].
PRO responses were collected using an electronic
tablet device prior to any other study-related activities,
at baseline (before randomization), every 3months
during the treatment phase and then every 6 months
until disease progression. All patients were educated on
the use of the electronic tablet. Interim results are
presented for the first 36 months of treatment.
Statistical methods
The primary analysis population was the intent-to-treat
(ITT) population (all randomized patients); the PRO
data set was the ITT population of patients with a base-
line and > 1 postbaseline PRO assessment. No imput-
ation of missing data or adjustments for multiplicity
were made. A sensitivity analysis was conducted using a
pattern-mixture model.
PRO data were summarized using descriptive statistics,
including number, mean, standard deviation, median,
and minimum and maximum value by treatment group.
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Compliance was calculated at baseline and for each post-
baseline PRO assessment visit as a percentage, with the
number of PRO assessments received as the numerator
and the number of PRO assessments expected at that
time point (a clinical prediction of how many patients
will be on treatment) as the denominator.
We assessed treatment differences using a repeated-
measures, mixed-effects model with a missing-at-random
data assumption. The model included the baseline PRO
score, treatment group, time, treatment by time inter-
action and the stratification factors as fixed effects and
subject as a random effect. A 2-sided 5% significance level
was used to descriptively compare values for the explora-
tory PRO endpoints, which are derived from scale scores.
The proportion of patients achieving minimally
important differences (MIDs) in each PRO instrument
scale score, which indicate clinically meaningful changes,
was summarized with odds ratios and 95% confidence
intervals (CIs). Although there is no universal MID [13],
there are multiple published MID thresholds ranging
from 5 to 10 [14–17]. Here, MID thresholds to explore
individual patient-level change were defined a priori as
10 points for the EORTC QLQ-C30 scale scores [18]
and ≥ 7 points for EQ-5D-5L VAS [19].
We conducted exploratory subgroup analyses to deter-
mine if there were differences in EORTC QLQ-C30
GHS, functional and symptom scale scores by age, and
Eastern Cooperative Oncology Group (ECOG) perform-
ance status. Exploratory analysis of time to worsening
using survival curves and hazard ratios (HRs) by depth
of clinical response and minimal residual disease (MRD)
status were estimated for EORTC QLQ-C30 scores.
Results
Patients
Baseline patient demographics and population characteris-
tics were similar between groups (D-VMP: n = 350; VMP:
n = 356) (Table 1). Mean age was 71 years, there were
approximately the same number of male and female pa-
tients, and approximately half of patients had a baseline
ECOG performance status of 1. Baseline EORTC QLQ-
C30 scores were similar between treatment arms for all
functional and symptom scales (Table 1).
Compliance rates with PRO measures were high and
similar across treatment groups. At baseline, 90.6 and
90.3% of patients subsequently assigned to the D-VMP
group and 91.9 and 91.3% of patients randomized to the
VMP group completed the EORTC QLQ-C30 and the
EQ-5D-5L, respectively (supplementary Fig. 1). Compli-
ance rates remained high (> 76%) throughout the study.
The number of PRO assessments received was higher in
the D-VMP group than in the VMP group, which is con-
sistent with the greater numbers of patients staying on
treatment with D-VMP compared with VMP. The PRO
data sets for the D-VMP group were also larger owing
to the longer treatment duration of these patients.
Treatment effect on EORTC QLQ-C30 scores
ITT population
Using a mixed-effects model with repeated measures,
the least squares (LS) mean change in GHS score from
Table 1 Baseline characteristics, EORTC QLQ-C30 scores and EQ-
5D-5L scores (ITT population)
Characteristic D-VMP (n = 350) VMP (n = 356)
Age, years
Mean (SD) 71.3 (6.66) 71.5 (5.82)
< 65, n (%) 36 (10.3) 24 (6.7)
65 to < 75, n (%) 210 (60.0) 225 (63.2)
≥ 75, n (%) 104 (29.7) 107 (30.1)
Male, n (%) 160 (45.7) 167 (46.9)
Race, n (%)
White 297 (84.9) 304 (85.4)
Black or African American 3 (0.9) 3 (0.8)
Asian 47 (13.4) 45 (12.6)
Other, Unknown or Not reported 3 (0.9) 4 (1.1)
ECOG performance status, n (%)
0 78 (22.3) 99 (27.8)
1 182 (52.0) 173 (48.6)
2 90 (25.7) 84 (23.6)
EORTC QLQ-C30 GHS score, mean (SD)
GHS 50.74 (20.996) 52.40 (22.691)
EORTC QLQ-C30 functional scores, mean (SD)
Physical functioning 59.96 (26.756) 63.65 (25.701)
Role functioning 57.54 (34.250) 61.06 (33.192)
Emotional functioning 69.70 (24.735) 71.10 (22.304)
Cognitive functioning 80.49 (21.998) 83.38 (19.948)
Social functioning 70.41 (28.468) 70.64 (28.651)
EORTC QLQ-C30 symptom scores, mean (SD)
Pain 46.10 (33.130) 43.12 (31.429)
Fatigue 42.48 (25.661) 41.05 (25.798)
Nausea/vomiting 5.38 (12.425) 5.45 (13.566)
Dyspnea 18.35 (24.930) 19.37 (24.742)
Insomnia 29.54 (30.044) 27.93 (31.135)
Appetite loss 22.26 (28.116) 21.81 (26.623)
Constipation 23.00 (31.517) 18.86 (27.404)
Diarrhea 5.91 (17.015) 5.40 (15.270)
Financial difficulties 18.88 (26.534) 17.33 (24.743)
EQ-5D-5L scores, mean (SD) (n = 316) (n = 325)
VAS 57.72 (20.254) 60.32 (20.556)
SD standard deviation
Higher EORTC QLQ-C30 scores represent greater GHS, better functioning and
worse symptoms. Higher EQ-5D-5L VAS score represents better health
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baseline was 7.3 in the D-VMP group and 3.9 in the
VMP group at 3 months (difference 3.4, p = 0.0240).
Between-group differences were not significant at other
assessment time points, but point estimates more often
favored the D-VMP group than the VMP group. The LS
mean change from baseline was clinically meaningful
(i.e. ≥10 points) at months 9, 12, 18 and 30 for both
treatment groups, as well as at month 24 in the VMP
group and month 36 in the D-VMP group (Fig. 1a).
LS mean changes from baseline were not significantly
different between treatment groups for the functional
scales of the EORTC QLQ-C30. Point estimates favored
the D-VMP group at all assessment time points for
physical functioning (Fig. 1b) and most time points for
role functioning, cognitive functioning and social func-
tioning (supplementary Fig. 2a, c, d). The direction of
the point estimates for between-group differences in
change in emotional functioning fluctuated depending
on the assessment time point, favoring D-VMP at
months 6, 12, 30 and 36 and favoring VMP at months 3,
9, 18 and 24 (supplementary Fig. 2b). LS mean change
from baseline in physical functioning scores was more
often clinically meaningful in the D-VMP group than in
the VMP group (6 vs 2 assessment time points). Clinic-
ally meaningful changes in role functioning scores were
observed in the D-VMP group at all time points after
month 3 and in the VMP group at all time points
between month 3 and month 30. LS mean changes in
emotional functioning scores were clinically meaningful
in both treatment groups at all assessment time points
after month 3. Scores for cognitive functioning declined
from baseline in both groups, but the LS mean change
from baseline was not clinically meaningful in either
group at any assessment time point.
There were no significant between-group differences
in LS mean change from baseline in scores for pain
(Fig. 1c), fatigue (Fig. 1d) or nausea and vomiting
(supplementary Fig. 2e). Point estimates generally
favored D-VMP for these symptoms. Improvements in
pain scores were clinically meaningful at all assessment
time points for both treatment groups, but were not
meaningful for either group at any time point for
fatigue or nausea and vomiting. Although overall usage
of concomitant medications was similar between
groups (97.7 and 96.9% of patients in the D-VMP and
VMP groups, respectively), greater proportions of
patients in the D-VMP group than in the VMP group
used analgesics (70.8% vs 57.9%) and anti-inflammatory
agents (25.7% vs 14.4%).
The proportions of patients with a clinically meaning-
ful change (i.e. ≥10 points) in EORTC QLQ-C30 scores
at month 36 are shown in Fig. 2. Differences between
treatment groups were not statistically significant, but
were numerically greater in the D-VMP group for all
scales. The greatest proportion of patients experienced
clinically meaningful changes in pain scores, with 75% of
patients in the D-VMP group and 71% of patients in the
VMP group reporting a mean change ≥10 points.
Subgroup analyses
In a subgroup analysis of EORTC QLQ-C30 GHS, phys-
ical functioning, pain and fatigue scores by age and
ECOG performance status, similar patterns of increasing
improvement in HRQoL were observed in all subgroups,
including patients 75 years of age or older and those
with poorer overall baseline functional status (ECOG
performance status ≥2), with no significant difference
between the D-VMP and VMP groups after 3 months
(Table 2). Improvements were observed in all subgroups,
but were generally greater in the younger (< 75 years) vs
older (≥75 years) patients and in those with ECOG per-
formance status of 2 vs those with ECOG performance
status of 0 or 1.
Time to worsening of GHS, function and symptoms was
generally longer with greater depth of clinical response
(Table 3). Time to worsening was significantly longer for pa-
tients with a complete response and significantly shorter for
patients with stable disease, both compared with patients
with very good partial response/partial response on the
EORTC QLQ-C30 GHS (hazard ratio = 0.72 and 1.75, re-
spectively). Similarly, patients who reached MRD-negative
status had significantly improved outcomes compared with
MRD-positive patients on EORTC QLQ-C30 GHS and pain
(hazard ratio = 0.70 and 0.60, respectively; p < 0.05).
Treatment effect on EQ-5D-5L scores
ITT population
At month 3, the LS mean difference from baseline in EQ-
5D-5L VAS score was 7 in the D-VMP group and 3.8 in
the VMP group (difference 3.1, p = 0.0160). Between-
group differences were not significant at other assessment
time points. Point estimates favored the D-VMP group at
months 6, 9, 18 and 36 and favored the VMP group at
months 12, 24 and 30 (Fig. 3a). The LS mean change was
clinically meaningful in both groups at month 18, in the
VMP group at month 24 and in the D-VMP group at
month 36. The proportion of patients with a clinically
meaningful improvement in VAS score was significantly
greater in the D-VMP group at month 3 (54.8% vs 41.3%,
odds ratio 1.72, p = 0.0025); between-group differences
were not significant at other time points (Fig. 3b). The
proportion of patients with clinically meaningful improve-
ment in VAS score was numerically greater in the D-VMP
group at all assessment time points except month 12.
Subgroup analyses
Similar to the subgroup analysis for EORTC QLQ-C30,
increasing improvement over time was observed for EQ-
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Fig. 1 LS mean change from baseline in EORTC QLQ-C30. a – GHS. b – Physical functioning. c – Pain. d – Fatigue up to 36months (ITT population)
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5D-5L VAS scores in subgroups by age and ECOG per-
formance status, with no significant difference between
treatment groups after 3 months (Table 2). Improve-
ments were greater in younger patients and those with
an ECOG performance status of 2.
Discussion
MM is incurable and was responsible for 1.1% of all can-
cer deaths worldwide in 2018 [20], and patients with
MM experience high levels of pain, fatigue and mood
disturbances [21]. MM treatments are often associated
with demanding administration and monitoring sched-
ules, as well as adverse events. As a result, the burden of
MM on patients’ HRQoL is substantial, and PROs
should be an important consideration for evaluating new
treatment strategies in these patients. This is particularly
relevant for the subpopulation of patients with NDMM
who are ineligible for transplant, as this group is
typically older and often has comorbidities, including
impaired renal and hepatic function, that may limit
therapeutic options and/or increase susceptibility to ad-
verse effects. Currently, data on HRQoL in this patient
subpopulation are limited.
The results presented here provide clear evidence of
the HRQoL benefits of D-VMP and VMP in patients
with NDMM who are not eligible for transplant. These
findings are consistent with a systematic review by
Nielsen et al. [22], which reported clinically relevant
improvement in HRQoL following treatment in this
population. Our study is the first to examine HRQoL of
patients treated with D-VMP, and the robustness of the
results was supported by a sensitivity analysis using a
pattern-mixture model.
Clinically meaningful improvements in GHS, function
and symptoms were maintained in this patient popula-
tion to at least 36 months, which corresponds to the
median overall survival of the control group in the Mye-
loma Trialists’ Collaborative Group meta-analysis of 24
randomized MM trials [23], and is likely among the
longest durations of follow-up reported in the first-line
treatment of transplant-ineligible patients with MM.
Baseline health status and burden of disease measured
using the EORTC QLQ-C30 GHS, functional scales and
symptom scales were worse for patients with NDMM
compared with a population-based random sample of
adults without cancer in Germany [24]. Nevertheless,
post-treatment scores improved to a level approaching
those of a noncancer population [25]. Improvements in
cognitive functioning were lower than those reported for
the other functional scales, but this is likely attributable
to a ceiling effect, as the mean baseline scores for the
cognitive functioning scale were the highest of the func-
tional scales, leaving little additional room for improve-
ment, especially in patients on active treatment. The
improvements in pain and fatigue observed with both D-
VMP and VMP may be particularly noteworthy. Prior
studies have demonstrated that patients with NDMM
tend to have more pain and fatigue than those with
later-stage disease [26], and a study by Jordan et al.
demonstrated that pain and fatigue are the strongest
predictors of HRQoL [27]. Treatments that impact these
symptoms may therefore have the largest impact on
patients’ HRQoL.
Although improvements in the D-VMP group were
statistically greater than those in the VMP group on
some scores at some time points, between-group differ-
ences were largely nonsignificant. This observation
needs to be considered in the context of the significant
increase in clinical benefits observed with the D-VMP
regimen [10]. One possible explanation for the lack of
incremental benefit for D-VMP over VMP on HRQoL
outcomes may be that this was an on-treatment analysis,
in which PRO results are reported for patients remaining
on treatment and do not reflect the impact of disease
progression resulting in discontinuation of study treat-
ment. A greater proportion of patients in the VMP
group compared with the D-VMP group discontinued
treatment owing to disease progression (13.3% vs 6.6%)
[10]. A second explanation may be the substantial posi-
tive impact of bortezomib on HRQoL. The magnitude of
Fig. 2 Percentage of patients reporting clinically meaningful improvements in EORTC QLQ-C30 functional and symptom scales at 36 months.
Clinically meaningful improvement defined as a ≥ 10-point improvement from baseline score
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symptom improvement observed in the present study is
noticeably larger than has been observed in some other
studies involving patients with NDMM who were trans-
plant ineligible. For example, the magnitude of the mean
changes in GHS, physical functioning, pain and fatigue
observed in the D-VMP and VMP groups in the present
trial is larger than those observed in the phase III FIRST
study of lenalidomide plus low-dose dexamethasone vs
melphalan/prednisone/thalidomide [28]. Although cross-
trial comparisons need to be interpreted with caution,
especially as patient inclusion criteria may differ, these
observations suggest that owing to the large improvement
Fig. 3 EQ-5D-5L VAS. a – LS mean change from baseline up to 36months. b – Percentage of patients reporting clinically meaningful
improvements up to 36months (ITT population)
Table 3 HRs for comparison of time to worsening of EORTC QLQ-C30 scale scores by depth of response and MRD status for pooled
treatment arms
EORTC QLQ-C30 scales Clinical response MRD− vs MRD+
(s)CR vs VGPR/PR SD vs VGPR/PR
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
GHS 0.72 (0.54–0.96) 0.025 1.75 (1.16–2.66) 0.008 0.70 (0.50–0.99) 0.042
Physical functioning 0.88 (0.66–1.17) 0.365 1.60 (0.05–2.45) 0.031 0.79 (0.57–1.10) 0.168
Role functioning 0.93 (0.72–1.20) 0.578 1.55 (1.05–2.27) 0.027 0.84 (0.62–1.12) 0.235
Emotional functioning 0.79 (0.57–1.07) 0.120 1.87 (1.21–2.88) 0.005 0.93 (0.66–1.31) 0.680
Cognitive functioning 0.81 (0.64–1.02) 0.075 1.28 (0.88–1.85) 0.200 1.02 (0.78–1.32) 0.910
Social functioning 0.87 (0.67–1.13) 0.290 1.50 (1.01–2.23) 0.044 0.89 (0.66–1.21) 0.453
Pain 0.72 (0.56–0.94) 0.017 1.22 (0.81–1.86) 0.340 0.60 (0.43–0.83) 0.002
Fatigue 1.01 (0.88–1.29) 0.950 1.44 (0.99–2.10) 0.060 0.98 (0.74–1.29) 0.023
Nausea/vomiting 1.05 (0.80–1.39) 0.733 1.38 (0.88–2.16) 0.158 0.92 (0.67–1.27) 0.610
Dyspnea 0.64 (0.48–0.84) 0.002 1.42 (0.94–2.15) 0.096 0.71 (0.51–0.98) 0.037
Insomnia 0.80 (0.62–1.04) 0.099 1.26 (0.84–1.90) 0.265 0.83 (0.61–1.12) 0.215
Appetite loss 1.05 (0.80–1.39) 0.716 1.67 (1.10–2.55) 0.017 0.96 (0.71–1.31) 0.596
Constipation 0.80 (0.61–1.06) 1.127 1.30 (0.84–2.02) 0.233 0.92 (0.67–1.26) 0.596
Diarrhea 1.03 (0.77–1.38) 0.832 1.39 (0.87–2.24) 0.172 0.89 (0.63–1.24) 0.475
PR partial response; (s)CR (stringent) complete response; SD stable disease; VGPR very good partial response
Worsening of EORTC QLQ-C30 GHS defined as a ≥ 10-point decrease and worsening of EORTC QLQ-C30 pain and fatigue defined as a ≥ 10-point increase
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in HRQoL with VMP alone and high baseline scores, there
was little additional room for improvement in HRQoL
upon further addition of daratumumab (i.e. ceiling effect).
Especially when it comes to depth of remission,
bortezomib-based regimens have consistently reported
greater proportions of patients in compete response when
compared with immunomodulatory drug–based combina-
tions. In ALCYONE, response assessment was comple-
mented by measurement of MRD rather than by pure
International Myeloma Working Group uniform response
criteria. In fact, patients who reached MRD-negative
status had significantly improved outcomes compared
with MRD-positive patients in terms of EORTC QLQ-
C30 GHS and pain scores.
Although patients were not randomized by subgroup,
and subgroup analyses should be interpreted with cau-
tion, results of these analyses were generally supportive
of the findings in the overall population. Subgroup
analyses also demonstrated symptom improvement with
both D-VMP and VMP irrespective of age and func-
tional status. Notably, improvements were observed in
patients 75 years of age or older and those with poor
overall function, indicating that the addition of daratu-
mumab did not negatively affect HRQoL, even in frail
and elderly patients who may have limited treatment op-
tions. The improvement in HRQoL in older patients is
noteworthy, as elderly patients tend to have greater
health impairment, including comorbidities, and so may
have a lower likelihood of achieving treatment benefit;
and transplant-ineligible patients tend to be older than
those who are eligible for transplant [26]. A further
subgroup analysis found that improvements in HRQoL
were greater for patients achieving the greatest clinical
response. This latter observation is consistent with the
results of previous studies that have demonstrated an
association between improved HRQoL outcomes and
depth of clinical response in patients with MM [29, 30].
Other studies have also examined the impact of dara-
tumumab as part of first-line treatment on HRQoL in
patients with transplant-eligible and -ineligible MM. In
the CASSIOPEIA study, daratumumab in combination
with bortezomib, thalidomide, and dexamethasone was
associated with significantly greater reductions in pain,
less deterioration of cognitive functioning and greater
improvements in emotional functioning vs bortezomib,
thalidomide and dexamethasone alone in patients with
transplant-eligible NDMM [31]. In the MAIA study, the
combination of daratumumab with lenalidomide and
dexamethasone was associated with faster and sustained
improvement in HRQoL measures compared with lenali-
domide and dexamethasone alone in patients with
transplant-ineligible NDMM [32]. In both the CASS
IOPEIA and MAIA studies, improvements in HRQoL
were consistent with observed clinical benefit. Our
results, the first in a study that includes an alkylator
agent, add to these existing data and demonstrate that
the combination of D-VMP improves HRQoL, with
meaningful improvements in both functional and symp-
tom scales in patients with transplant-ineligible NDMM.
As noted above, the improvements in PROs reported
here complement the significant clinical benefits ob-
served with D-VMP vs VMP, including a lower risk of
disease progression and higher percentages of patients
with MRD negativity. PROs provide the patient perspec-
tive on treatment, and use of clinical endpoints and
PROs together best reflect the full spectrum of patients’
disease as well as the overall effectiveness of treatment.
However, whereas the clinical assessments showed sig-
nificant improvements with D-VMP vs VMP [10], in-
cluding significant improvements in overall survival [33],
differences in HRQoL between groups were modest and
largely nonsignificant. In addition to the two explana-
tions provided above, this disparity could be due to the
use of generic PRO instruments in the ALCYONE trial.
MM-specific PRO measures with greater sensitivity to
changes in HRQoL, symptoms and impacts for compar-
ing two treatments with multiple drugs may have been
able to tease out the treatment differences with greater
specificity, although the EORTC QLQ-C30 and EQ-5D-
5L are validated tools that are widely used to assess
HRQoL in patients with cancer.
One of the limitations of the present study is the
open-label design, which may lead to biased treatment
effects on PROs. As noted above, another limitation is
that only on-treatment results are presented, as patients
were censored from the analysis when they discontinued
treatment, so HRQoL outcomes do not reflect disease
progression (and more patients in the VMP group
progressed and discontinued treatment). Furthermore, no
reasons were documented for missing data, and some
consequences of treatment may not have been identified.
This study is also limited by the lack of control for the use
of pain medication. Nonsteroidal anti-inflammatory drugs
are not recommended in patients with MM because of
renal toxicity [34], yet 25.7% of patients in the D-VMP
group and 14.4% in the VMP group were treated with these
agents, and the proportion of patients treated with
analgesic, low-dose corticosteroid and anti-inflammatory
medications was greater in the D-VMP group than in the
VMP group. It is not possible to determine to what extent
these medications may have contributed to the decreases in
pain observed in the study, although the impact of systemic
corticosteroids is likely minimal given the high cumulative
dose of prednisone patients received as part of their study
treatment. Furthermore, the difference in the proportion of
patients treated with these agents while on study treatment
may be explained, at least in part, by the fact that more
patients remained on treatment in the D-VMP group.
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In conclusion, patients with NDMM who were
transplant ineligible demonstrated early and continuous
improvements in HRQoL, including improvements in
function and symptoms following treatment with D-
VMP or VMP. Functional status and well-being were
maintained in patients who remained in the study for
both the D-VMP and VMP treatment groups, and
support the clinical efficacy benefits already reported
[10]. This analysis highlights the importance of measur-
ing HRQoL and PROs to confirm the benefits of cancer
therapy on the day-to-day aspects of patients’ lives, as
well as their clinical prognoses.
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